Claims for Patent: 5,942,510

Summary for Patent: 5,942,510

Title:	Pharmaceutical composition containing lamotrigine
Abstract:	A lyophilized formulation of lamotrigine having been prepared by lyophilizing a frozen sterile aqueous solution of Imotrigine mesylate in which the pH is from 2.4 to 4.
Inventor(s):	Floyd; Alison Green (Raleigh, NC), Jain; Sunil (Cary, NC)
Assignee:	Glaxo Wellcome Inc. (Research Triangle Park, NC)
Application Number:	08/973,798
Patent Claims:	1. A lyophilized formulation of lamotrigine having been prepared by lyophilizing a substantially frozen sterile solution of lamotrigine mesylate and at least one bulking agent in which the pH of said solution is from 2.5 to 4. 2. A lyophilized formulation of lamotrigine having been prepared by lyophilizing a substantially frozen sterile solution of lamotrigine mesylate and at least one bulking agent in which the pH of said solution is from 2.8 to 3.5. 3. A lyophilized formulation of lamotrigine having been prepared by lyophilizing a substantially frozen sterile solution of lamotrigine mesylate and at least one bulking agent in which the pH of said solution is from 3.3 to 3.5. 4. A formulation according to claim 1, wherein the concentration of lamotrigine mesylate prior to lyophilization, calculated as the free base, is from 1 to 60 mg/ml. 5. A formulation according to claim 2, wherein the concentration of lamotrigine mesylate prior to lyophilization, calculated as the free base, is from 1 to 60 mg/ml. 6. A formulation according to claim 3, wherein the concentration of lamotrigine mesylate prior to lyophilization, calculated as the free base, is from 1 to 60 mg/ml. 7. A formulation according to claim 1, wherein the concentration of lamotrigine mesylate prior to lyophilization, calculated as the free base, is from 20 to 30 mg/ml. 8. A formulation according to claim 2, wherein the concentration of lamotrigine mesylate prior to lyophilisation, calculated as the free base, is from 20 to 30 mg/ml. 9. A formulation according to claim 3, wherein the concentration of lamotrigine mesylate prior to lyophilization, calculated as the free base, is from 20 to 30 mg/ml. 10. A formulation according to claim 2, wherein the solution is wholly or substantially aqueous. 11. A lyophilized formulation of lamotrigine having been prepared by lyophilizing a substantially frozen sterile solution of lamotrigine mesylate and at least one bulking agent selected from the group consisting of mannitol, dextrose, lactose, sucrose, sorbitol and glycine in which the pH of said solution is from 2.5 to 4. 12. A formulation according to claim 11, wherein the pH of said solution is from 2.8 to 3.5. 13. A formulation according to claim 11, wherein the concentration of lamotrigine mesylate prior to lyophilization, calculated as the free base, is from 20 to 30 mg/ml. 14. A formulation according to claim 11, wherein the bulking agent is present in an amount of about 192 to 470 mg. 15. A formulation according to claim 11, wherein the bulking agent is mannitol. 16. A formulation according to claim 1, wherein lamotrigine mesylate is formed from lamotrigine free base and methanesulphonic acid, the free base and acid being present in a substantially equimolar ratio. 17. An injectable formulation containing lamotrigine mesylate, reconstituted from a lyophilized formulation of claim 1 using a sterile carrier suitable for intravenous administration, wherein the concentration of lamotrigine mesylate is in the range of 1 to 60 mg/ml, calculated as the free base. 18. An injectable formulation containing lamotrigine mesylate, reconstituted from a lyophilized formulation of claim 1 using a sterile carrier suitable for intravenous administration, wherein the concentration of lamotrigine mesylate is in the range of 1 to 20 mg/ml calculated as the free base. 19. An injectable formulation containing lamotrigine mesylate, reconstituted from a lyophilized formulation of claim 1 using a sterile carrier suitable for intravenous administration, wherein the concentration of lamotrigine mesylate is in the range of 1 to 20 mg/ml, calculated as the free base and wherein the pH of said reconstituted injectable formulation is 3.4 to 4. 20. An injectable formulation containing lamotrigine mesylate, reconstituted from a lyophilized formulation of claim 1 using a sterile carrier suitable for intravenous administration, wherein the concentration of lamotrigine mesylate is in the range of 1 to 60 mg/ml, calculated as the free base, and wherein said sterile carrier suitable for intravenous administration is sterile water for injection or 5% dextrose solution. 21. An injectable formulation containing lamotrigine mesylate, reconstituted from a lyophilized formulation of claim 11 using a sterile carrier suitable for intravenous administration, wherein the concentration of lamotrigine mesylate is in the range of 1 to 20 mg/ml, calculated as the free base and wherein the pH of said reconstituted injectable formulation is 3.4 to 4. 22. An injectable formulation containing lamotrigine mesylate, reconstituted from a lyophilized formulation of claim 11 using a sterile carrier suitable for intravenous administration, wherein the concentration of lamotrigine mesylate is in the range of 1 to 20 mg/ml, calculated as the free base wherein the pH of said reconstituted injectable formulation is 3.4 to 4 and wherein the concentration of said bulking agent is 12 to 47 mg/ml. 23. A method of treating a patient with epilepsy, which method comprises intravenously administering to the patient an injectable formulation according to claim 11. 24. A process for preparing a lyophilized formulation of lamotrigine, which process comprises lyophilizing a substantially frozen sterile aqueous solution of lamotrigine mesylate and at least one bulking agent in which the pH of said solution is from 2.5 to 4. 25. A process for preparing a lyophilized formulation of lamotrigine, which process comprises lyophilizing a substantially frozen sterile aqueous solution of lamotrigine mesylate and at least one bulking agent in which the pH of said solution is from 2.8 to 3.5. 26. A process for preparing a lyophilized formulation of lamotrigine according to claim 25, wherein at least one bulking agent selected from the group consisting of mannitol, dextrose, lactose, sucrose, sorbitol and glycine is included in the aqueous solution prior to lyophilization. 27. A process for preparing a lyophilized formulation of lamotrigine according to claim 25, wherein the bulking agent, mannitol is included in the aqueous solution prior to lyophilization.

Details for Patent 5,942,510

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2015-06-23